Alkermes Plc
NASDAQ:ALKS

Watchlist Manager
Alkermes Plc Logo
Alkermes Plc
NASDAQ:ALKS
Watchlist
Price: 29.71 USD -0.87% Market Closed
Market Cap: 4.8B USD
Have any thoughts about
Alkermes Plc?
Write Note
Section:
 

Relative Value

The Relative Value of one ALKS stock under the Base Case scenario is 26.98 USD. Compared to the current market price of 29.71 USD, Alkermes Plc is Overvalued by 9%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALKS Relative Value
Base Case
26.98 USD
Overvaluation 9%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.2
P/S
P/S
Price to Sales
3.2
vs History
46
vs Industry
77
Median 3Y
3.3
Median 5Y
3.1
Industry
7.6
Forward
3.1
More Details
14.4
P/E
P/E
Price to Earnings
14.4
vs History
12
vs Industry
10
Median 3Y
-27.1
Median 5Y
-27.6
Industry
22.1
Forward
10.9
More Details
13.5
P/OCF
P/OCF
Price to OCF
13.5
vs History
76
vs Industry
12
Median 3Y
24.2
Median 5Y
36.2
Industry
21.9
More Details
15.4
P/FCFE
P/FCFE
Price to FCFE
15.4
vs History
53
vs Industry
9
Median 3Y
16.1
Median 5Y
16.1
Industry
23.4
More Details
3.7
P/B
P/B
Price to Book Value
3.7
vs History
41
vs Industry
28
Median 3Y
3.7
Median 5Y
3.5
Industry
2.5
More Details
2.8
EV/S
EV/S
Enterprise Value to Sales
2.8
vs History
50
vs Industry
68
Median 3Y
3
Median 5Y
2.8
Industry
7.5
Forward
2.7
More Details
3.3
EV/GP
EV/GP
Enterprise Value to Gross Profit
3.3
vs History
50
vs Industry
67
Median 3Y
3.6
Median 5Y
3.4
Industry
9.3
More Details
8.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
8.8
vs History
36
vs Industry
11
Median 3Y
8.9
Median 5Y
7.3
Industry
4.2
Forward
9.5
More Details
9.6
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
9.6
vs History
14
vs Industry
9
Median 3Y
-26.8
Median 5Y
-24.9
Industry
4
Forward
10.6
More Details
11.8
EV/OCF
EV/OCF
Enterprise Value to OCF
11.8
vs History
76
vs Industry
13
Median 3Y
21.5
Median 5Y
33.1
Industry
5.9
More Details
13.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.3
vs History
52
vs Industry
9
Median 3Y
13.6
Median 5Y
13.6
Industry
3.9
More Details
3.5
EV/IC
EV/IC
Enterprise Value to IC
3.5
vs History
12
vs Industry
41
Median 3Y
3.2
Median 5Y
2.8
Industry
4.5
More Details

Multiples Across Competitors

ALKS Competitors Multiples
Alkermes Plc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Alkermes Plc
NASDAQ:ALKS
4.8B USD 3.2 14.4 8.8 9.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 5.6 61.1 15.2 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 4.4 33.5 16 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 4.1 915.4 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 9.6 -213.4 21 22.1
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 5.6 16.6 15.1 16.7
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
35.7B EUR 19.2 -134.7 -108.7 -79.2
P/S Multiple
Revenue Growth P/S to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/S: 3 457 240.2
3.2
-9%
N/A
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.2
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average P/E: 178.8
14.4
2%
6.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
61.1
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
915.4
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -213.4
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -134.7 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBITDA: 15.1
8.8
-55%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.2
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Alkermes Plc
NASDAQ:ALKS
Average EV/EBIT: 19.6
9.6
-30%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.2 N/A N/A

See Also

Summary
ALKS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ALKS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ALKS stock valuation using valuation multiples.
Wall Street Estimates
ALKS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ALKS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.